With many GPs no longer seeing sales representatives, pharmaceutical companies should be prepared to engage and support GPs under a digitally led model.
How a GP initiated engagement model could be the way forward for the pharmaceutical industry
COVID-19 created opportunities for pharmaceutical companies to find new ways to engage with GPs. While face-to-face rep visits are likely to remain integral, it’s clear that increasingly time-poor GPs are seeking synthesised, relevant insights in a timely manner and want to drive the engagement on their terms.
How do busy GPs want to find out about new medications?
With the TGA having registered 99 new medicines so far in 2024 (as at 26/09/2024) and the PBS updating its schedule several times a year, we explored how GPs prefer to find out about new medicines. According to one study, GPs are unlikely to spontaneously go looking for information about new medicines. Instead, they are
Can chat bots replace pharmaceutical representatives? (From the perspective of a bot)
Given the scripted nature placed on pharma sales reps and their communication with doctors, do new technologies such as chat bots create the opportunity to deliver these messages in a better way? Chatbots can provide a convenient and cost-effective way for doctors and pharma sales reps to communicate, enabling doctors to access the product information
3 AusDoc innovations to support your brands, reps and events to achieve maximum HCP engagement
Do you want to boost your lead generation and increase GP touchpoints 6-fold? The new Access.PLUS Sample and Service requests package has already proved itself with 2,000+ doctor lead generations and 3,000+ sample requests for 10 pharma companies. The package is designed to improve the efficiency of your field force by generating more touchpoints for
Are MSLs the untapped opportunity for Pharma to better support GPs?
GPs have a low understanding of the difference between medical science liaisons (MSLs) and pharmaceutical sales reps, according to a recent survey conducted by AusDoc.1 The finding is unsurprising, given that MSLs generally focus on other specialists. But the increasing complexity of GP work means they will likely receive increasing MSL attention in the future.
Putting an Aussie lens on Veeva’s global omnichannel report
The recent Veeva Pulse Field Trends Report 2Q22[i] provided valuable insight into when, where and how field teams and healthcare professionals interact with the pharmaceutical industry representatives. However, the global report didn’t’ offer any Australia-specific findings. To fill this gap, Inside Healthcare conducted a similar study among AusDoc’s extensive GP database to provide deeper insights
Overburdened GPs tell AusDoc about plans to work fewer hours and increase fees
GPs feel burdened by their workload and poorly compensated for their time, according to a survey of 750 Australian Doctor readers. More than 40% of the respondents intend to reduce their working hours in the next 12 months. In many cases, this is coupled with a change from bulk billing to private billing so they
Discover better with the new AusDoc community platform
AusDoc has become a whole lot better. We are evolving into a community platform, allowing doctors to connect with their colleagues across the medical profession as well as keeping them informed with the latest news, opinion, clinical updates and education. Given the ever-growing complexity of medicine, a community where doctors can discuss and debate the
How can pharma companies fill the gap in digital delivery?
Global report shows excitement about the potential of digital but a lack of confidence about delivery Pharma companies need to invest in the digital customer experience to add value now and in the future, according to a report by digital customer experience agency Graphite in partnership with Reuters Events. The global report titled the Contradiction Conundrum is
How to cover twice as many GPs without increasing your budget
A hybrid model that combines reps with digital solutions is a win-win for pharmaceutical companies and GPs. With face-to-face rep engagement returning to pre-COVID levels, pharmaceutical companies have an opportunity to use digital lessons learned during the pandemic to significantly increase the reach and frequency of their GP interactions without increasing their budget. The solution
How a digital engagement campaign achieved low-cost GP registrations to a pharma company’s microsite
Building an opted-in HCP database and attracting HCPs to sign up to microsites is an ongoing challenge for pharmaceutical companies. This campaign illustrates the cost effectiveness of digital engagement solutions such as Access.PLUS to successfully drive APHRA-verified HCP sign-ups.